Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$38.96 USD

38.96
4,990,122

-0.25 (-0.64%)

Updated Oct 17, 2024 04:00 PM ET

After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date

by Zacks Equity Research

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.

AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status

by Zacks Equity Research

The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.

Should Value Investors Buy GlaxoSmithKline (GSK) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

by Kinjel Shah

Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.

Kinjel Shah headshot

4 Big Drugmakers to Bet on After a Great Earnings Season

by Kinjel Shah

Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.

Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study

by Zacks Equity Research

GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.

Merck's Ebola Vaccine Gets Conditional Approval in Europe

by Zacks Equity Research

European Commission grants approval to Merck's (MRK) Ervebo (V920) for active immunization of individuals 18 years and above to protect against Ebola Virus Disease caused by Zaire Ebola virus.

Novartis' Generics Unit to Buy Aspen's Japanese Operations

by Zacks Equity Research

Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.

Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase

by Zacks Equity Research

Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.

Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales

by Zacks Equity Research

Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.

Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates

by Zacks Equity Research

Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.

Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

Sanghamitra Saha headshot

Value Biotech ETFs & Stocks to Buy Now

by Sanghamitra Saha

Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

by Zacks Equity Research

Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y

by Zacks Equity Research

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.

Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Novo Nordisk (NVO) beats earnings estimates but misses sales estimates in the third quarter of 2019.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates

by Kinjel Shah

Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.

What's in the Cards for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be reported quarter.

Bristol-Myers (BMY) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Bristol-Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View

by Zacks Equity Research

Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.

Glaxo (GSK) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Glaxo (GSK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Rise Y/Y

by Zacks Equity Research

Bayer's (BAYRY) earnings beat and revenues rise on the back of growth across all reported segments in the third quarter. The company updates guidance to include impact of discontinued operations.

Glaxo (GSK) Beats Earnings & Revenue Estimates in Q3

by Zacks Equity Research

Glaxo beats both earnings and sales estimates in the third quarter of 2019.

AMETEK (AME) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

AMETEK's (AME) third-quarter results are expected to reflect benefits of growth strategies and acquisitions, and solid momentum across segments.